

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chackalannil et al.) Group Art Unit: 1617
)
Serial No.: 10/705,282) Examiner: Carlic K. Huynh
)
Filed: November 10, 2003) Date: January 3, 2007
)
For: Methods of Use of Thrombin) Confirmation No. : 4919
Receptor Antagonists)
)
Docket No.: CV01185K1X)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Sir:

This communication is in response to the Official action mailed December 1, 2006, in the subject patent application.

Claims 1-39 are pending in the case. The Examiner has restricted the invention into two groups:

Group I: Claims 1-8, drawn to methods of treating a therapeutic condition comprising administering at least one compound of formula (I); and,

Group II: Claims 9-39 drawn to methods of treating a therapeutic condition comprising administering at least one compound of formula (II).

Where an election of Group I or Group II is made, the Examiner additionally required the election of a single disclosed compound of formula (I) or (II), respectively, as well as a single disclosed species of a condition. It was further required that a listing of all claims readable on the elected species be provided. Upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 C.F.R. §1.141.

Election

Applicants elect the invention cited as Invention Group II defined as Claims 9-39 by the Examiner. Applicants further elect the species compound of the formula of

Claim 17 (which is the same as the compound of Claims 18-24), and the species therapeutic condition of acute coronary syndrome, as recited in Claim 10.

In reliance on the above, Applicants expect to be entitled to consideration of claims to additional species upon allowance of a generic claim, and reserve the right to prosecute non-elected subject matter in subsequently filed divisional applications. In particular, Applicants expect to pursue the prosecution of claims to species compounds other than that of Claim 17 and species conditions (both cardiovascular and non-cardiovascular) other than acute coronary syndrome.

Examination on the merits for claims 9-39 is respectfully requested.

If the Examiner has questions, the Examiner is invited to contact the undersigned.


AUTHORIZATION

The Office action to which this paper is responsive was mailed on December 1, 2006 with a shortened statutory period for reply set to expire one month or thirty days, whichever is longer, from the mailing date. The one-month date fell on January 1, 2007 which was a federal holiday, New Years Day. A federal holiday was declared on the following day, January 2, 2007, in remembrance of the death of President Ford.

This Response to Election/Restriction Requirement is filed on the first day after a two consecutive federal holidays and, in view of the provisions of 37 C.F.R. §1.7, is believed to be filed before the expiration of the one-month shortened statutory period for reply. Thus, Applicants respectfully submit that no fee is necessary. However, should such fee become necessary to render this Response timely filed, the Commissioner is authorized to draw the required amount from Applicants' deposit account no. 19-0365.

January 3, 2007

Respectfully submitted,


Gerard E. Reinhardt
Registration No. 43,041
Attorney for Applicants
Tel: 908-298-2960
Fax: 908-298-5388